辅助纳武利尤单抗联合伊匹单抗治疗期间隐匿性检查点抑制剂心肌炎：一种潜伏但严重的毒性。
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.
机构信息
1st Medical Oncology Department, Neon Faliron, Athens.
Department of Medicine, University of Crete, Heraklion, Greece.
出版信息
Immunotherapy. 2024;16(14-15):937-942. doi: 10.1080/1750743X.2024.2385286. Epub 2024 Sep 11.
Abstract
Checkpoint inhibitor myocarditis is a rare but life-threatening toxicity of immunotherapy, occasionally manifesting as persistent troponin elevation. Dual checkpoint blockade with ipilimumab and nivolumab has been found to induce immune-related myocarditis in patients with metastatic melanoma. We herein report a case of smoldering immune-related myocarditis in a 54-year-old male after a single infusion of nivolumab plus ipilimumab as adjuvant treatment for completely resected stage IV melanoma. High-dose steroid treatment resulted in decrease in the levels of cardiac enzymes, without any major complications.
摘要
检查点抑制剂性心肌炎是一种罕见但危及生命的免疫治疗毒性反应，偶尔表现为持续性肌钙蛋白升高。伊匹单抗和纳武单抗的双重检查点阻断已被发现可诱导转移性黑色素瘤患者发生免疫相关性心肌炎。我们在此报告一例 54 岁男性病例，在完全切除的 IV 期黑色素瘤接受纳武单抗联合伊匹单抗辅助治疗后，单次输注后出现亚临床免疫相关性心肌炎。大剂量类固醇治疗可降低心肌酶水平，且无任何重大并发症。
相似文献
1
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.辅助纳武利尤单抗联合伊匹单抗治疗期间隐匿性检查点抑制剂心肌炎：一种潜伏但严重的毒性。
Immunotherapy. 2024;16(14-15):937-942. doi: 10.1080/1750743X.2024.2385286. Epub 2024 Sep 11.
2
Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma.纳武利尤单抗和伊匹木单抗诱发一名转移性黑色素瘤患者发生肌炎、重症肌无力和心肌炎。
Anticancer Drugs. 2025 Aug 1;36(7):600-605. doi: 10.1097/CAD.0000000000001727. Epub 2025 Apr 23.
3
Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.免疫检查点抑制剂在恶性黑色素瘤中的比较性严重皮肤毒性：一项系统评价和网状荟萃分析
J Cosmet Dermatol. 2024 Apr;23(4):1165-1177. doi: 10.1111/jocd.16105. Epub 2023 Nov 27.
4
Neoadjuvant treatment for stage III and IV cutaneous melanoma.新辅助治疗 III 期和 IV 期皮肤黑色素瘤。
Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.
5
Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient.一名黑色素瘤患者接受伊匹单抗和纳武单抗联合免疫治疗后发生细支气管炎
J Immunother. 2024 Sep 1;47(7):263-265. doi: 10.1097/CJI.0000000000000509. Epub 2024 Feb 27.
6
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.新辅助纳武利尤单抗和伊匹单抗治疗可切除 III 期黑色素瘤。
N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2.
7
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort.一项针对罕见肿瘤的双抗CTLA-4和抗PD-1阻断的II期篮子试验（DART）SWOG S1609：高钙血症型卵巢小细胞癌队列中的持久反应和延迟假性进展
Cancer Commun (Lond). 2025 May 22. doi: 10.1002/cac2.70020.
8
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.CheckMate 238 研究中辅助性检查点抑制剂治疗后复发的系统性治疗结局
J Clin Oncol. 2024 Nov;42(31):3702-3712. doi: 10.1200/JCO.23.01448. Epub 2024 Aug 5.
9
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.单药或双药免疫检查点抑制剂作为晚期黑色素瘤的辅助治疗
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
10
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.新辅助双免疫检查点抑制剂与抗 PD-1 治疗高危可切除黑色素瘤的疗效比较：一项汇总分析。
JAMA Oncol. 2024 May 1;10(5):612-620. doi: 10.1001/jamaoncol.2023.7333.
本文引用的文献
1
A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?免疫检查点抑制剂诱发心肌炎的系统评价：免疫检查点抑制剂最常见的心脏毒性有多令人担忧？
Cureus. 2023 Jul 18;15(7):e42071. doi: 10.7759/cureus.42071. eCollection 2023 Jul.
2
Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review.纳武单抗和伊匹单抗所致多器官功能衰竭：一例报告及文献综述
Cureus. 2023 Jul 12;15(7):e41781. doi: 10.7759/cureus.41781. eCollection 2023 Jul.
3
Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review.免疫检查点抑制剂相关心肌炎和心肌病：一项转化医学综述
Biology (Basel). 2023 Mar 20;12(3):472. doi: 10.3390/biology12030472.
4
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.免疫疗法毒性的管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18.
5
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.纳武利尤单抗/雷莫芦单抗：不可切除或转移性黑色素瘤免疫检查点抑制剂治疗的新选择。
Ann Pharmacother. 2023 Jun;57(6):738-745. doi: 10.1177/10600280221131396. Epub 2022 Oct 21.
6
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.伊匹单抗和纳武单抗治疗晚期黑色素瘤的真实世界疗效：一项多中心回顾性研究。
Eur J Cancer. 2022 Nov;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub 2022 Oct 7.
7
Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy.纳武利尤单抗和伊匹单抗联合化疗治疗非小细胞肺癌所致暴发性心肌炎。
Intern Med. 2023 May 1;62(9):1319-1322. doi: 10.2169/internalmedicine.0505-22. Epub 2022 Sep 21.
8
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药用于无疾病证据的 IV 期黑色素瘤患者的辅助治疗（IMMUNED）：一项随机、双盲、II 期试验的最终结果。
Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10.
9
Checkpoint Immunotherapy-Induced Myocarditis and Encephalitis Complicated With Complete AV Block: Not All Hope Is Lost.免疫检查点疗法诱导的心肌炎和脑炎并发完全性房室传导阻滞：并非全无希望。
JACC Case Rep. 2022 Aug 17;4(16):1032-1036. doi: 10.1016/j.jaccas.2022.04.020.
10
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
Zotero 插件